A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 352 participants.

Also called NCT07839585

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 352 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07839585
  • EU CT 2025-524634-25-00
  • WHO UTN U1111-1331-4324
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07839585. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-26 (anticipated); primary completion 2030-01-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Acronym
CHORUS
Intervention (Biological)
Sotatercept
Intervention (Biological)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct07839585
Content hash
7899206fb3a4f5d0235d23f3371f02df8dc070277da5c147dc58a24ee2f78470